Janux Therapeutics, Inc. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

AnaptysBio, Inc.

Janux Therapeutics, Inc.

Avidity Biosciences, Inc.

Alector, Inc.

Entrada Therapeutics, Inc.

Dyne Therapeutics, Inc.

Anavex Life Sciences Corp.

4D Molecular Therapeutics, Inc.

Allogene Therapeutics, Inc.

HilleVax, Inc.

AN2 Therapeutics, Inc.

Why is Janux Therapeutics, Inc. ?

Negative results in Jun 25

OPERATING CASH FLOW(Y) Lowest at USD -59.79 MM
DEBTORS TURNOVER RATIO(HY) Lowest at 0.05 times
RAW MATERIAL COST(Y) Grown by 101.07% (YoY)

Risky - Negative EBITDA

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -28.84%, its profits have fallen by -39.9%

Underperformed the market in the last 1 year

Even though the market (S&P 500) has generated returns of 12.33% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -28.84% returns

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Janux Therapeutics, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Janux Therapeutics, Inc.

-72.6%

-0.24

81.94%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-74.03%

EBIT Growth (5y)

-239.68%

EBIT to Interest (avg)

-63.89

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.00

Sales to Capital Employed (avg)

0.02

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.54

EV to EBIT

-4.84

EV to EBITDA

-4.93

EV to Capital Employed

550.17

EV to Sales

58.93

PEG Ratio

Dividend Yield

ROCE (Latest)

-11358.30%

ROE (Latest)

-7.68%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

Bearish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Bullish

Mildly Bearish

Dow Theory

Mildly Bullish

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

3What is working for the Company

NET PROFIT(HY)

Higher at USD -57.37 MM

DEBT-EQUITY RATIO (HY)

Lowest at -98.31 %

-23What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at USD -59.79 MM

DEBTORS TURNOVER RATIO(HY)

Lowest at 0.05 times

RAW MATERIAL COST(Y)

Grown by 101.07% (YoY

OPERATING PROFIT(Q)

Lowest at USD -44.58 MM

PRE-TAX PROFIT(Q)

Lowest at USD -33.86 MM

NET PROFIT(Q)

Lowest at USD -33.86 MM

EPS(Q)

Lowest at USD -0.55

Here's what is working for Janux Therapeutics, Inc.

Debt-Equity Ratio

Lowest at -98.31 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Here's what is not working for Janux Therapeutics, Inc.

Pre-Tax Profit

At USD -33.86 MM has Fallen at -74.21%

over average net sales of the previous four periods of USD -19.44 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -33.86 MM has Fallen at -74.21%

over average net sales of the previous four periods of USD -19.44 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Debtors Turnover Ratio

Lowest at 0.05 times and Fallen

In each half year in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Operating Cash Flow

Lowest at USD -59.79 MM

in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Operating Profit

Lowest at USD -44.58 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (USD MM)

Pre-Tax Profit

Lowest at USD -33.86 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit

Lowest at USD -33.86 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

EPS

Lowest at USD -0.55

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (USD)

Raw Material Cost

Grown by 101.07% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales